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Review Article
Meta-Analysis of Scalp Acupuncture for Acute
Hypertensive Intracerebral Hemorrhage
Guo-qing Zheng, MD, PhD,1,2 Zhi-Ming Zhao, PhD,3 Yan Wang, MD, PhD,2 Yong Gu, MD, PhD,1
Yue Li, PhD,1 Xing-miao Chen, PhD,1 Shu-Ping Fu, MD, PhD,1 and Jiangang Shen, MD, PhD1
Abstract
Objectives: Scalp acupuncture (SA) is a commonly used therapeutic approach for primary intracerebral hem-
orrhage (ICH) in Traditional Chinese Medicine (TCM), but the efficacy and safety of SA therapy are still
undetermined. The aim of this study is to systematically evaluate the efficacy and safety of SA therapy for the
treatment of acute hypertensive ICH.
Methods: Literature reports with randomized controlled clinical trials and controlled clinical trials on SA therapy
for acute hypertensive ICH were searched, and the efficacy and safety of SA therapy were evaluated by using the
Cochrane systematic review methods. The primary outcome measures were death or dependency at the end of
long-term follow-up (at least 3 months) and adverse events. The secondary outcome measure was neurological
deficit improvement at the end of the treatment course.
Results: Seven (7) independent trials (230 patients) were included in this study. All trials described the methods
of randomization in which four trials had adequate concealment of randomization at the level of grade A, but no
trial included sham acupuncture as a control group. None of the trials included ‘‘death or dependency’’ as a
primary outcome measure. Four (4) trials contained safety assessments and stated that no adverse event was
found, whereas the other three trials did not provide the information about adverse events. By using random
effects statistical model, it was found that patients with acute hypertensive ICH who received SA therapy had
significantly improved neurological deficit scores (Z¼ 4.97, p< 0.01).
Conclusions: Although SA therapy is widely used to treat acute hypertensive ICH in TCM, the efficacy and
safety of SA therapy remain to be further determined. No evidence is available on whether SA therapy can be
used to treat acute ICH according to the primary outcome measure. However, SA therapy appears to be able to
improve neurological deficit in patients with acute hypertensive ICH.
Introduction
Primary intracerebral hemorrhage (ICH), the mostdevastating form of stroke, accounts for 10%–15% of
stroke victims. ICH has more severe neurological deficits and
higher mortality rates than ischemic stroke. ICH secondary to
pathologic changes initiated by chronic hypertension is re-
sponsible for *75% of all cases of primary ICH.1,2 ICH has
three main pathophysiologic phases: arterial rupture and
hematoma formation, hematoma enlargement, and perihe-
matoma edema. Up to 40% of the hematomas grow in the first
hours postrupture. ICH growth is associated with early clin-
ical deterioration. The volume of ICH directly affects clinical
outcome, and approximately one third of ICH cases have a
growing volume of hematoma at 3–24 hours after onset.3,4
Early interventions to reduce ICH volume might be useful for
improving clinical outcome. A recent meta-analysis with 10
randomized controlled trials indicates that surgical treatment
could reduce the chances of death or disability. Surgical
treatment is a likely benefit for those patients with altered
consciousness or neurological deterioration.5 However, a
large randomized clinical trial (RCT) that involved 1033 pa-
tients from 83 centers in 27 countries failed to show a benefit of
surgery over conservative treatment in acute ICH.6 Apart
from surgical invention, conservative treatments with medi-
cations that stop bleeding are potential therapeutic strategies
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to prevent or decrease hematoma growth. For instances, fac-
tor VII, aminocaproic acid, tranexamic acid, and aprotinin
may enhance hemostasis in patients with normal coagula-
tion.7 Two (2) RCTs indicate that recombinant factor VIIa is
promising to limit hematoma growth and improve outcome,
but it was associated with an increase in thromboembolic
complications.8,9 Until now, there has been no effective ther-
apeutic approach with sufficient evidence to improve the
clinical outcome of ICH.
China has a relatively higher incidence of hemorrhagic
stroke than Western countries do.10 Traditional Chinese
Medicine (TCM) was a major available health care system
before modern Western medicine was introduced to China.11
TCM therapies including acupuncture, herbal medicine, and
other nonmedication therapies have been used for treating
patients with stroke for thousand years. Scalp acupuncture
(SA), also called cranial acupuncture or cephalic acupunc-
ture, is a modality to stimulate different scalp zones corre-
sponding to various brain areas with needles so as to excite
the reflex-related nervous tissues and promote recovery of
neurological functions.12 The SA is one of the major ap-
proaches for poststroke disability in acupuncture treatment.
The SA was originally developed from cranial acupoints of
acupuncture therapy in ancient China, which could be dated
back to 5 bc.13 Modern SA therapy was derived from tradi-
tional acupuncture in combination with the basic principles
of neuroanatomy and neurophysiology. Since the World
Health Organization (WHO) approved the international
standard scalp acupuncture point lines and the brain func-
tional domain projection in 1991,14 SA therapy has been ex-
tensively applied for the treatment of brain disorders in
China.15 SA therapy is considered an essential therapeutic
protocol for rehabilitation of neurological disability in is-
chemic stroke treatment.16 SA therapy is also used for acute
ICH. The first clinical observation on efficacy of SA therapy
for acute ICH was described in the 1990s,17,18 and now SA
therapy has become a popular therapeutic protocol for acute
ICH treatment in TCM. However, both experimental studies
and clinical trials are not sufficient for evaluating the efficacy
and safety of SA therapy for acute ICH treatment.
In this study, to evaluate the efficacy and safety of SA
therapy for acute ICH, a literature search was conducted and
the existing clinical evidence was reviewed on SA therapy
for acute hypertensive ICH by using the Cochrane systematic
review methods. This study indicates that SA therapy is a
potentially promising therapy for recovery of neurological
deficits induced by acute hypertensive ICH, but it will be
necessary to conduct well-designed clinical trials to evaluate
clinical outcomes in the future.
Study Criteria
Types of studies
Randomized controlled clinical trials for evaluating the
effects of SA therapy on acute ICH with at least one control
group receiving modern standardized treatment or conven-
tional treatment were included in the study.
Types of participants
Trials that included patients of any age or sex with acute
hypertensive ICH (within 14 days since onset) were eligible.
The diagnostic criteria were adopted in accordance with the
following: (1) Diagnosis of hypertension was made on the
basis of the ‘‘Definition and Classification of Hypertension’’
in 1999 from WHO–International Society of Hypertension
(ISH) Guidelines for the Management of Hypertension19; (2)
Diagnosis of ICH was made on the basis of the Chinese
national criteria of cerebral hemorrhage in Diagnostic Essen-
tials of Various Cerebrovascular Diseases revised at the Fourth
National Conference of P. R. China Society of Medicine on
Cerebrovascular Diseases in 1995.20 As computed tomogra-
phy/magnetic resonance imaging (CT/MRI) scans are es-
sential for the diagnosis of ICH, all of the patients were
examined with CT/MRI scanning in the trials.
Types of interventions
The clinical trials were included regardless of the number
of times of treatment or the length of treatment period, but
acupoint selection must be limited to the head, in which ear
acupoints should be excluded. Either traditional acupuncture
or electroacupuncture was included, regardless of the sour-
ces or methods of stimulation (e.g., scalp penetration acu-
puncture or electrical stimulation). The patients of the control
group were given modern conventional treatments. The pa-
tients at the trial groups were given SA therapy in addition
to the baseline medication similar to the control groups.
Types of outcome measurements
The primary outcome measurement was death or depen-
dency at the end of long-term follow-up of at least 3 months
and adverse events. The secondary outcome measurement
was the scores of neurological deficit improvement at the end
of the treatment course. The criteria of neurological deficit
score were adopted based on the Modified Edinburgh–
Scandinavian Stroke Scale, a nationwide accepted scoring
system recommended at the Second and revised at the Fourth
National Cerebrovascular Diseases Conference in China, in-
cluding consciousness, gaze, facial paresis, language, walking
ability, motor function of arms, legs, and hands.20,21 The as-
sessment was conducted in accordance with the reduction in
the scores of basic nervous functional deficits and disability
degree as follows: Recovery scores—The functional deficit
scores were decreased up to 91%–100%, and disability degree
was at grade 0; Remarkable Improvement—The scores of
functional deficit were decreased at 46%–90%, and disability
degree was at the grade 1–3; Improvement—The scores of
functional deficit were decreased at 18%–45%; No change—
The scores of functional deficit were decreased or increased at
about 17%; Deterioration—The scores of functional deficit
were increased over 18%.
Literature Search
Computer-based retrieval was performed by using
PubMed and Cochrane library (until October 2009) in En-
glish, and using full-text database of Chinese periodicals in
China National Knowledge Infrastructure (until October
2009) in Chinese by 2 reviewers (Z.M.Z. and G.Q.Z.). The key
words used for the search were scalp acupuncture/head
acupuncture/cranial acupuncture/cephalic acupuncture/
scalp electric acupuncture/scalp penetration acupuncture
and intracerebral hemorrhage. The types of publication
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searched were clinical trials and reviews. The reference lists
of all relevant articles were searched for further studies.
Data Extraction and Quality Assessment
Two (2) review authors (Z.M.Z. and G.Q.Z.) indepen-
dently assessed all studies. The same 2 review authors in-
dependently extracted eligible data from the trial reports
onto a data extraction form, and data were cross-checked for
accuracy before use. Disagreement was resolved by discus-
sion with a third-party reviewer ( J.G.S.) if necessary. The
authors of the trials were contacted and asked to provide
missing data.
Quality assessment was conducted to determine whether
the trials met the following internal validity criteria: (1)
method of randomization (truly or quasirandomized); (2)
adequate allocation concealment; (3) blinding (both of par-
ticipants and outcome assessors); (4) participant dropout and
loss to follow-up; (5) intention-to-treat (ITT) analysis.
Data Analysis
Heterogeneity between trial results was tested using a
standard w2 test. The results were reported as Peto-odds ra-
tios with corresponding 95% confidence intervals for di-
chotomous data. If continuous data were available, weighted
mean difference or standardized mean difference was to be
calculated. The figures were obtained from the statistical
software provided by the Cochrane Collaboration (RevMan
4.2.10).
Results
Search strategy and general information
On the basis of search strategy, we retrieved 21 relevant
reports published from 1991 to 2009. After reading through
all the reports, we found seven reports of definite or possible
RCTs and controlled clinical trials.22–24*,{,{,§ The remaining 14
reports were excluded because they were uncontrolled ob-
servational studies, or duplicate publications, or with pa-
tients who did not meet the criteria of the types of
participants. A total of 230 patients with acute hypertensive
ICH from seven reports were included. All trials were con-
ducted in China and published from 2003 to 2007 (Table 1).
The ages of patients in the studies were all above 45 years.
Each trial included more men than women. All selected trials
applied conventional diagnostic criteria for ICH with Chi-
nese National Criteria and for Hypertension with WHO-ISH
Guidelines,19,20 although many trials also included TCM di-
agnostic criteria. All patients had undergone a CT/MRI
scanning to confirm the diagnosis. The starting time point for
SA therapy was within 14 days after stroke. The total period
for SA therapy varied from 10 to 28 days. The patients in the
included trials received SA therapy plus modern conven-
tional treatment. One (1) trial was performed with surgical
intervention.24 In all of the trials, neurological deficit was
measured with the Modified Edinburgh–Scandinavian
Stroke Scale.19,20
Quality of the Trials
All of the trials described the methods of randomization,
including random number generator (calculator) and draw-
ing method. Four (4) trials described grade A level of ade-
quate concealment of randomization, in which the patients
were allocated according to calculator random numbers
sealed in opaque envelopes (see footnotes *,{,{,§). The ran-
domized, single blind, baseline treatment controlled trials
were described in these four trials. However, no trial in-
cluded sham acupuncture as a control group. The remaining
three trials did not mention blinding or ITT analysis.22–24 All
trials conducted a comparable analysis between scalp treat-
ment group and control group, although the raw statistical
data are not elaborated in detail.
Death or Dependency
None of the trials used these as primary outcome mea-
sures.
Adverse Events
No adverse event was mentioned in three trials.22,24(footnote {)
Safety assessments were conducted in the other four trials,
and no obvious adverse event was found.21,23(footnotes *,{,§)
No significant change was observed in the clinical bio-
chemical tests including routine blood, urine and stool tests,
myocardial enzymes, liver functions, and renal function be-
fore and after the SA treatments.23(footnotes *,{,§) In one trial, a
series of studies were conducted on the safety of applying SA
therapy for ICH at acute stage (footnote {). There were no
significant changes in heart rate, respiration, blood pressure,
or oxygen saturation among the selected time points in-
cluding 2 hours prior to the SA treatments, during the
treatments, and 2 hours after the treatments. Interestingly,
head CT scan showed that the absorption rate of hematoma
in the SA group (76.67%) was significantly improved com-
pared with those in the control group (56.67%) at the time
points before and after the treatments. In the SA groups, the
abnormal rates of electrocardiography decreased from
73.33% to 16.67% after receiving the designed treatments,
whereas in the control group it was decreased from 70% to
43.33% after the designed treatments.
Neurological Deficit Improvement
The seven independent trials22–24(footnotes *,{,{,§) did not
show homogeneity in the consistency of the trial results
(w2¼ 17.43, p< 0.01). Thus, the random-effect model should
be used for statistical analysis. In the random-effect statistical
model, the combined effects of seven independent trial re-
sults showed that patients with acute hypertensive ICH
*Zhao GJ. Clinical study on acute hypertensive intracerebral
hemorrhage with penetrating of scalp-point the study on therapeutic
effect and somatosensory evoked potential. MPhil thesis, Hei-
longjiang University of Traditional Chinese Medicine, 2003.
{Zhang SY. Acute hypertensive intracerebral hemorrhage clinical
paired observation and serum NSE correlativity study with scalp-
acupoint penetrating acupuncture therapy. MPhil thesis, Hei-
longjiang University of Traditional Chinese Medicine. 2005.
{Yuan P. Clinical and basic research of security on acute cerebral
hemorrhage by acupuncture scalp point-through-point therapy. PhD
thesis, Heilongjiang University of Traditional Chinese Medicine,
2007.
§Li JJ. Study of scalp penetration acupuncture on serum S100B
protein and IGF-1 in blood of patients with acute intracerebral
hemorrhage. MPhil Thesis, Heilongjiang University of Traditional
Chinese Medicine, 2005.
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receiving SA therapy had significantly improved neurologi-
cal deficit scores when compared with the control group
(Z¼ 4.97, p< 0.01, Fig. 1).
Bias Determination
Publication bias was found in the included seven inde-
pendent references. One (1) trial had serious bias, whereas
the other six trials had relatively slight bias in the evaluations
of the clinical outcomes. These six trials also confirmed the
positive effects of SA therapy for improving neurological
deficit scores in acute hypertensive ICH (Fig. 2).
Discussion
This is the first meta-analysis for evaluating the clinical
outcome of SA therapy for acute ICH. The results indicate that
SA therapy appears to be effective for improving neurological
deficit scores in patients with acute hypertensive ICH.
Experimental and clinical studies suggest that SA therapy
might be a useful therapeutic approach for poststroke neu-
rological dysfunctions, but its mechanisms still are largely
unknown. Theoretically, SA therapy can stimulate specific
scalp areas corresponding to the functional areas of cerebral
cortex. SA needle stimulation can effectively raise blood flow
volume in the common carotid artery, leading to an increase
of the energy supply of the cerebral blood circulation in
patients who have had a stroke.25 Functional magnetic res-
onance imaging (fMRI) study revealed that SA therapy in-
creased brain oxygen content in healthy volunteers.26
Experimental stroke studies suggest that SA stimulation
could regulate the expressions of cytokines, inflammation
factors, and transcriptional factors in ischemia–reperfused
brains. For instance, in rat models of acute cerebral ischemia–
reperfusion injury, SA stimulation suppressed the expres-
sions of nuclear factor–kB, cyclo-oxygenase-2, tumor necrosis
factor-a, and interleukin-1b, inhibited leukocyte infiltra-
tion, and enhanced the expression of transforming growth
factor-b1 in rat brains, subsequently attenuating cerebral
ischemia–reperfusion injury and improving neurofunctional
rehabilitation.27,28 A fMRI study on a hypertensive stroke
rat model revealed that SA stimulation reduced vasogenic
edema and reduced neurological dysfunction.29 As most
studies focus on ischemic stroke in current reports, stud-
ies on SA therapy for acute ICH are insufficient experi-
mentally and clinically. The effectiveness and safety of
SA therapy for acute ICH treatment have not been evaluated
with current rigorous international standards. Therefore,
it is very urgent and important to assess the quantity, qual-
ity, and overall strength of SA therapy for acute ICH treat-
ment.
In this meta-analysis, we found that the primary outcomes
were inadequately designed in all of the included clinical
trials. There were unknown dropout rates and definitional
vagueness in the measurement. The duration of therapy and
the follow-up period were not long enough to achieve con-
clusive results. None of the studies included endpoints such
FIG. 1. Neurologic deficit improvement after treatment with scalp acupuncture versus control. SD, standard deviation;
WMD, weighted mean difference; CI, confidence interval.
FIG. 2. Funnel plot of the comparison
of clinical effects of scalp acupuncture with
those of control groups. SE, standard
error; WMD, weighted mean difference.
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as the rates of death, the rate of dependency, survival times,
or reduction in length of staying in hospital or long-term
care. Thus, there was no evidence available about the effect
of SA therapy on the rates of death or dependency at the end
of follow-up (at least 3 months). The other primary outcome
was adverse effects. Owing to the rapid onset, the dangerous
condition and high mortality of hemorrhagic stroke, some
academics were skeptical about SA for acute ICH (see foot-
note {). They remarked that SA was not suitable for acute
ICH. The major concern was that external stimulus might
affect the stability of hematoma and increase the risks of
cerebral edema and hematoma growth. According to the
safety assessment of the four trials in this systematic re-
view,23(footnotes *,{,§) SA therapy for acute ICH is generally
safe. However, intensive investigations with relatively large
scales and high standard in experimental design are pre-
required before SA therapy is recommended for common
clinical application.
The most noticeable finding is that SA therapy was simi-
larly effective in all of the clinical trials based on the sec-
ondary outcomes in the improvement of neurological deficit
scores. The effects could be real, but they could also be at-
tributable to the potential bias and to the methodological
quality of the included trials. Publication bias could be a
factor. There are several methodological limitations in the
clinical trials. First, the blinding procedures could be a factor
because all of the trials did not design sham acupuncture as
the control group. In the design of clinical trials for acu-
puncture research, the comparison of SA and sham treat-
ments with the blind or double-blind clinical experiments is
extremely difficult. With a restrict standard of blind control
in RCTs, if the patients have a sensation at the points of
needle contact, it could not be considered a valid blind
control. The same problem arises in double-blinding proce-
dures used in physical therapy, surgical procedures, den-
tistry, and so on. Therefore, developing an effective method
for sham acupuncture will be critical in the future. Second,
the included trials were generally of small sample size. None
of the trials reported the method of determination of the
sample size. Third, the scheduled treatment period ranged
from 14 days to 28 days in the included trials. All of the
follow-ups were terminated at the end of the treatment pe-
riod. Three (3) months after the onset of stroke could be an
appropriate time to measure the neurological outcome, be-
cause the recovery of neurological deficit occurred quickly in
first 3 months after symptom onset. Nevertheless, although
current clinical trials could not lead to drawing a conclusion,
the results do provide some promising data indicating that
SA therapy can improve outcomes in the neurological deficit
scores. Given that SA therapy is widely used for acute ICH
by TCM practitioners, a blind placebo-controlled RCT in-
cluding primary and second outcomes becomes a timely
important issue. In addition, using fMRI or other brain im-
aging modalities to monitor hematoma growth in experi-
mental ICH animal models and clinical trials is also a critical
research topic in this field.
Conclusions
In conclusion, insufficient evidence is available to support
the routine use of SA for acute ICH according to the primary
measure of efficacy. However, SA therapy appears to be
generally safe and can be used in the acute stage of ICH. SA
therapy may have beneficial effects on neurological impair-
ment, but this efficacy needs to be further confirmed by
methodologically rigorous trials. The key for evidence-based
practices is to design and conduct appropriate RCTs with
adequate concealment of allocation, blinding of outcome as-
sessors and sham acupuncture control, and establishment of a
consensus on standardized relevant outcome measurements.
The primary outcome and relatively long-term follow-up are
also important. If SA therapy can improve the clinical out-
come of acute ICH as confirmed with the evidence-based
medicine approaches, SA therapy will be an important con-
tribution of TCM to human health care worldwide.
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